Vestibular toxic effects induced by once-daily aminoglycoside therapy

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 1, 2005, Pages 46-48

  Dhanireddy, Shireesha ^a   Liles, W Conrad ^a   Gates, George A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; VANCOMYCIN;

ADULT; ARTICLE; ATAXIA; BACTERIAL INFECTION; CASE REPORT; DISEASE EXACERBATION; DIZZINESS; DRUG WITHDRAWAL; FEMALE; HEARING ACUITY; HEARING IMPAIRMENT; HUMAN; MALE; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; OTOTOXICITY; PHYSICAL EXAMINATION; VESTIBULAR DISORDER; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; MALE; MIDDLE AGED; VESTIBULAR DISEASES;

EID: 12144282767     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.131.1.46     Document Type: Article

References (18)

1. Brummet RE, Fox KE. Studies of aminoglycoside ototoxicity in animal models. In: Whelton A, Neu HC, eds. The Aminoglycoside: Microbiology, Clinical Use, and Toxicity. New York, NY: Marcel Dekker Inc; 1982:419-451.
2. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993;341:335-339.
3. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991;35:399-405.
4. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809.
5. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med. 1986;80:98-104.
6. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39:677-686.
7. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532.
8. Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis. 2003;36:615-621.
9. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900-911.
10. Laurent G, Carlier MB, Rollman B, Van Hoof F, Tulkens P. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol. 1982;31:3861-3870.
11. Nakashima T, Teranishi M, Hibi T, Kobayashi M, Umemura M. Vestibular and cochlear toxicity of aminoglycosides: a review. Acta Otolaryngol. 2000;120:904-911.
12. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000;5:3-22.
13. Schacht J. Biochemistry and pharmacology of aminoglycoside-induced hearing loss. Acta Physiol Pharmacol Ther Latinoam. 1999;49:251-256.
14. Matsui JI, Hague A, Huss D, et al. Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo. J Neurosci. 2003;23:6111-6122.
15. Schacht J. Antioxidant therapy attenuates aminoglycoside-induced hearing loss. Ann N Y Acad Sci. 1999;884:125-130.
16. Basile AS, Huang JM, Xie C. NMDA antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med. 1996;2:1338-1343.
17. Fetoni AR, Sergi B, Scarano E, Paludetti G, Ferraresi A, Troiani D. Protective effects of alpha-tocopherol against gentamicin-induced otovestibulotoxicity: an experimental study. Acta Otolaryngol. 2003;123:192-197.
18. Black FO, Ginanna-Poulin C, Pesznecker SC. Recovery from vestibular ototoxicity. Otol Neurotol. 2001;22:662-671.